HPV VIM study (H-54674)

The primary goal of this study is to determine the effect of intratumoral HPV vaccination with topical imiquimod and oral metformin on 24-month progression-free survival in patients with locally advanced cervical, vaginal or vulvar carcinoma. This treatment will be administered alongside definitive whole pelvic radiotherapy, chemotherapy and brachytherapy. The aim is to monitor tumor response, symptom relief, safety and tolerability to assess whether this combination therapy offers a therapeutic benefit.